Fujiwara Hisataka, Aoki Kiichi, Nakaya Tsutomu, Akiyama Yuji, Kimura Yusuke, Iwaya Takeshi, Saito Kazuyoshi
Dept of Surgery, Yamamoto Kumiai General Hospital.
Gan To Kagaku Ryoho. 2004 Nov;31(12):2035-8.
The patient was a 72-year-old female with gastric carcinoma. A liver metastatic recurrence was detected 27 months after operation. Although temporary partial responses were obtained by each effective chemotherapy, which was a combination chemotherapy with 5'-DFUR and TXT, TS-1 and TXL, the metastatic lesion proved refractory to all of them. Then we tried combination chemotherapy consisting of CDDP 30 mg/m2 and CPT-11 60 mg/m2, respectively (day 1 and 15, every 4 weeks). A partial response was achieved and continued for 8.5 months, and her complaints abated and quality of life improved. Although gastro-intestinal symptoms and bone marrow suppression were observed as side effects, they were within a tolerable range and did not interfere with the combination therapy. This regimen appears to be feasible and effective for recurrent gastric carcinoma refractory to other regimens.
该患者为一名72岁的女性胃癌患者。术后27个月检测到肝转移复发。尽管通过每种有效的化疗(即5'-DFUR与TXT、TS-1与TXL的联合化疗)都获得了暂时的部分缓解,但转移病灶对所有这些化疗均耐药。然后我们尝试了分别由顺铂30mg/m²和伊立替康60mg/m²组成的联合化疗(第1天和第15天,每4周一次)。获得了部分缓解并持续了8.5个月,她的症状减轻,生活质量得到改善。尽管观察到胃肠道症状和骨髓抑制作为副作用,但它们在可耐受范围内,并未干扰联合治疗。该方案对于对其他方案耐药的复发性胃癌似乎是可行且有效的。